Studies in Pharmaceutical EconomicsCRC Press, 1996. okt. 11. - 586 oldal Readers of Studies in Pharmaceutical Economics learn the value of economic research in forming health policy while they develop an understanding of the various factors that influence the cost of pharmaceutical care for patients, pharmacists, physicians, and manufacturers. Pharmaceutical economists, product managers, and policymakers learn different methods for controlling costs, patient compliance, therapeutic outcomes, and the effects of restrictions on prescription drugs on the use and cost of other health care services. Above all, readers will find this book provides them with the necessary `know-how’for survival in the dynamic and competitive health care marketplace.The chapters of Studies in Pharmaceutical Economics range in scope from editorials to technical papers on new research methods. Readers will find the following key topics covered:
|
Részletek a könyvből
1 - 5 találat összesen 84 találatból.
ix. oldal
... Outcomes of Pharmacoeconomic Analysis 238 Perspective Analysis 239 Conclusions Chapter 16. QALYs in Health Outcomes Research : Representation.
... Outcomes of Pharmacoeconomic Analysis 238 Perspective Analysis 239 Conclusions Chapter 16. QALYs in Health Outcomes Research : Representation.
x. oldal
Mickey Smith. Conclusions Chapter 16. QALYs in Health Outcomes Research : Representation of Real Preferences or Another Numerical Abstraction ? 247 251 Dev S. Pathak Introduction 251 QALY : In Theory and in Practice 252 Measurement of Y ...
Mickey Smith. Conclusions Chapter 16. QALYs in Health Outcomes Research : Representation of Real Preferences or Another Numerical Abstraction ? 247 251 Dev S. Pathak Introduction 251 QALY : In Theory and in Practice 252 Measurement of Y ...
xii. oldal
... Outcomes 346 350 Conclusion 356 Chapter 23. Pricing and Perspectives 359 Joseph D. Jackson Introduction 359 The Medicaid Rebate Program 360 The Pharmaceutical Industry The U. S. Health Care Environment Solutions : Outcomes and Value 361 ...
... Outcomes 346 350 Conclusion 356 Chapter 23. Pricing and Perspectives 359 Joseph D. Jackson Introduction 359 The Medicaid Rebate Program 360 The Pharmaceutical Industry The U. S. Health Care Environment Solutions : Outcomes and Value 361 ...
xxi. oldal
Sajnáljuk, az oldal tartalma korlátozott hozzáférésű..
Sajnáljuk, az oldal tartalma korlátozott hozzáférésű..
25. oldal
Sajnáljuk, az oldal tartalma korlátozott hozzáférésű..
Sajnáljuk, az oldal tartalma korlátozott hozzáférésű..
Tartalomjegyzék
PUBLIC POLICY ISSUES | 1 |
An Independent Assessment | 10 |
Health Policy Initiatives and the Utility | 18 |
of Economic Research | 25 |
Specific Policies and Concerns About Methodologies | 31 |
Paying | 39 |
Conclusion | 66 |
INTERVENTIONS AND CONTROLS | 83 |
Conclusion | 288 |
Physicians Perceptions of Prescription Drug | 305 |
Beliefs and Opinions | 314 |
Methods | 322 |
Discussion | 328 |
An Exploratory Study of Physician Perceptions | 335 |
Limitations | 343 |
Toward an Understanding of Pharmaceutical | 345 |
Estimation Procedures | 96 |
Incorporating SeverityofIllness Measures | 103 |
Initial Impact of a Medicaid Prior | 113 |
Conclusion and Discussion | 124 |
Data and Methods | 130 |
Conclusion | 137 |
Impact of an Open Formulary System | 143 |
Results | 149 |
Discussion | 159 |
Limitations | 165 |
A Research Framework for Economic | 171 |
Summary | 179 |
Fundamental Concepts of Economic Analysis | 186 |
Assessment of a Contingent Valuation | 193 |
Results | 201 |
Discussion | 207 |
Using Repeated Measures Designs | 215 |
Dependent Measures | 222 |
Magnitude of Effects | 228 |
Methods | 234 |
Measurement of QALY | 257 |
Issues in the Measurement of QALY | 264 |
PRICES AND PRICING | 273 |
The German Prescription Drug System | 281 |
Conclusion | 356 |
The U S Health Care Environment | 370 |
Outcomes and Value | 378 |
Conclusion | 386 |
for Medical Technology | 391 |
Research Method | 393 |
Discussion and Conclusions | 401 |
DirecttoConsumer Advertising | 408 |
The Role of Health Economics in Marketing | 415 |
Entry Prices | 433 |
ECONOMICS OF NONCOMPLIANCE | 441 |
Introduction | 467 |
The Conceptual Model | 478 |
EFFECTS ON PHARMACY | 481 |
The Tools of Managed Care | 494 |
Provider Reimbursement in Public Programs | 500 |
Effects of Managed Care of Pharmacy Services | 506 |
Analysis of the Impact of ThirdParty | 517 |
Results and Analysis | 523 |
ThirdParty Associated CostShift Pricing | 531 |
Pharmacy Participation in ThirdParty | 545 |
Strategic Implications | 554 |
Más kiadások - Összes megtekintése
Gyakori szavak és kifejezések
administrative admissions adverse drug reactions advertising allergic rhinitis analgesic analysis antihistamine assessment associated average number behavior benefits capitation capitation rate claims clinical consumers contingent valuation contracts cost-effectiveness coverage decision differences dispensing drug cost drug orders drug product drug therapy effects eligible enrollee estimates expenditures factors Figure firms glyburide health care hospital impact included increase inpatient Journal limit managed managed care means measures Medicaid Medicaid patients Medicare method noncompliance nonprescription NSAID number of prescriptions onychomycosis open formulary outcomes outpatient overall percentage period Pharm Pharmaceutical Economics pharmaceutical industry pharmacists pharmacoeconomic pharmacy physicians prescribing prescription drug prescription price private payment private-pay profits promotion providers QALY regimen regression reimbursement reported response restrictions sample scription significant statistical strategy Table Terbinafine therapeutic third-party prescription tion treatment trend unclaimed prescriptions utility variables